Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A

FEBS Letters

Volumn 416, Issue 3, 1997, Pages 230-234

  Walsh, Aimée H ^a   Cheng, Aiyang ^a   Honkanen, Richard E ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Antitumor activity; Cantharidin; Dephosphorylation; Fostriecin; Inhibitor; Okadaic acid; Phosphatase; Protein; Serine threonine; Toxin; Tumor promotion

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; FOSTRIECIN; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DOSE RESPONSE; ENZYME INHIBITION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

ALKENES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BRAIN; CATTLE; ENZYME INHIBITORS; ISOENZYMES; KINETICS; MUSCLE, SKELETAL; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLASE KINASE; PYRONES; RABBITS; RECOMBINANT FUSION PROTEINS;

STREPTOMYCES PULVERACEUS;

EID: 0030720062     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-5793(97)01210-6     Document Type: Article

References (46)

1. Stampwala S.S., Bunge R.H., Hurley T.R., Willmer N.E., Brankiewicz A.J., Steinman C.E., Smitka T.A., French J.C. J. Antibiot. (Tokyo). 36:1983;1601-1605.
2. Tunac J.B., Graham B.D., Dobson W.E. J. Antibiot. (Tokyo). 36:1983;1595-1600.
3. de Jong R.S., de Vries E.G., Mulder N.H. Anticancer Drugs. 8:1997;413-418.
4. Scheithauer W., Von Hoff D.D., Clark G.M., Shillis J.L., Elslager E.F. Eur. J. Cancer Clin. Oncol. 22:1986;921-926.
5. Leopold W.R., Shillis J.L., Mertus A.E., Nelson J.M., Roberts B.J., Jackson R.C. Cancer Res. 44:1984;1928-1932.
6. Fry D.W., Boritzki T.J., Jackson R.C. Cancer Chemother. Pharmacol. 13:1984;171-175.
7. Boritzki T.J., Wolfard T.S., Besserer J.A., Jackson R.C., Fry D.W. Biochem. Pharmacol. 37:1988;4063-4068.
8. Roberge M., Tudan C., Hung S.M., Harder K.W., Jirik F.R., Anderson H. Cancer Res. 54:1994;6115-6121.
9. Guo X.W., Th'ng J.P., Swank R.A., Anderson H.J., Tudan C., Bradbury E.M., Roberge M. EMBO J. 14:1995;976-985.
10. Ho D.T., Roberge M. Carcinogenesis. 17:1996;967-972.
11. Bialojan C., Takai A. Biochem. J. 250:1988;283-290.
12. Cohen P., Holmes C.F.B., Tsukitani Y. Trends Biochem. Sci. 15:1990;98-102.
13. Honkanen R.E., Zwiller J., Moore R.E., Daily S., Khatra B.S., Dukelow M., Boynton A.L. J. Biol. Chem. 265:1990;19401-19404.
14. MacKintosh C., Beattie K.A., Klumpp S., Cohen P., Codd G.A. FEBS Lett. 264:1990;187-192.
15. Fujiki H., Suganuma M. Adv. Cancer Res. 61:1993;143-194.
16. Ohta T., Nishiwaki R., Yatsunami J., Komori A., Suganuma M., Fujiki H. Carcinogenesis. 13:1992;2443-2447.
17. Honkanen R.E. FEBS Lett. 330:1993;283-286.
18. Li Y.M., Casida J.E. Proc. Natl. Acad. Sci. USA. 89:1992;11867-11870.
19. Walter W.G. J. Pharmacol. Sci. 78:1989;66-67.
20. Ruiting C., Ze H., Jinlong Y., Jiaxian H., Suyin Z., Feili L., Bin X. Chinese Med. J. 93:1980;183-187.
21. Sjöholm Å., Honkanen R.E., Berggren P.O. Biosci. Rep. 13:1993;349-358.
22. Ämmälä C., Eliasson L., Bokvist K., Berggren P.O., Honkanen R.E., Sjöholm Å., Rorsman P. Proc. Natl. Acad. Sci. USA. 91:1994;4343-434724.
23. Brautigan D.L., Shriner C.L. Methods Enzymol. 159:1988;339-347.
24. Honkanen R.E., Dukelow M., Moore R.E., Zwiller J., Khatra B.S., Boynton A.L. Mol. Pharmacol. 40:1991;577-583.
25. Honkanen R.E., Mowdy D.E., Dickey R.W. J. AOAC Int. 79:1996;1336-1343.
26. Brautigan D.L., Shriner C.L., Gruppuso P.A. J. Biol. Chem. 260:1985;4295-4302.
27. Critz S.D., Honkanen R.E. Neuroprotocols. 6:1995;78-83.
28. Honkanen R.E., Codispoti B.A., Tse K., Boynton A.L. Toxicon. 32:1994;339-350.
29. Pallas D.C., Shahrink L.K., Martin B.L., Jaspers S., Miller T.B., Brautigan D.L., Roberts T.M. Cell. 60:1990;167-176.
30. Killilea S.D., Aylward J.H., Mellgren R.L., Lee E.Y.C. Arch. Biochem. Biophys. 191:1978;638-646.
31. Barik S. Methods Neurosci. 26:1995;309-323.
32. Zhang J., Zhang Z., Brew K., Lee E.Y. Biochemistry. 35:1996;6276-6282.
33. Zhang Z., Zhao S., Bai G., Lee E.Y. J. Biol. Chem. 269:1994;13766-13770.
34. Bagu J.R., Sykes B.D., Craig M.M., Holmes C.F. J. Biol. Chem. 272:1997;5087-5097.
35. Huang H.B., Horiuchi A., Goldberg J., Greengard P., Nairn A.C. Proc. Natl. Acad. Sci. USA. 94:1997;3530-3535.
36. Honkanen R.E., Caplan F.R., Baker K.K., Baldwin C.L., Bobzin S.C., Bolis C.M., Cabrera G.M., Johnson L.A., Jung J.H., Larsen L.K., Levine I.A., Moore R.E., Nelson C.S., Patterson G.M.L., Tschappat K.D., Tuang G.D., Boynton A.L., Arment A.R., An J., Carmichael W.W., Rodland K.D., Magun B.E., Lewin R.A. J. Phycol. 31:1995;478-486.
37. Carmichael W.W., Beasley V., Bunner D.L., Eloff J.N., Falconer I., Gorham P., Harada K., Kirshnamurthy T., Yu M.-J., Moore R.E., Rinehart K.L., Runnegar M., Skulberg O.M., Watanabe M. Toxicon. 26:1988;971-973.
38. Jackson R.C., Fry D.W., Boritzki T.J., Roberts B.J., Hook K.E., Leopold W.R. Adv. Enzyme Regul. 23:1985;193-215.
39. Ishihara H., Martin B.L., Brautigan D.L., Karaki H., Ozaka H., Kato Y., Fusetani N., Watabe S., Hashimoto K., Uemura D., Hartshorne D.J. Biochem. Biophys. Res. Commun. 159:1989;871-877.
40. MacKintosh C., Klumpp S. FEBS Lett. 277:1990;137-140.
41. Hori M., Magae J., Han Y.-G., Hartshorne D.J., Karaki H. FEBS Lett. 285:1991;145-148.
42. Chen X.C., Ubukata M., Isono K. J. Antibiot. 63:1990;809-819.
43. Cohen P. Annu. Rev. Biochem. 58:1989;453-508.
44. Shenolikar, S. and Nairn, A.C. (1991) In: Advances in Second Messenger and Phosphoprotein Research (Greengard P. and Robinson, G.A., Eds.) Vol. 23, pp. 3-119, Raven Press, New York.
45. Fry D.W., Besserer J.A., Boritzki T.J. Cancer Res. 44:1984;3366-3370.
46. Goldberg J., Huang H.B., Kwon Y.G., Greengard P., Nairn A.C., Kuriyan J. Nature. 376:1995;745-753.